Group 1: Recent IPOs - Last week, 15 new stocks were listed, including one direct listing company, Public Policy Holding (PPHC), which raised $50.84 million by issuing 4.15 million shares at $12.25 per share [1] - York Space System (YSS) raised $629 million by issuing 18.5 million shares at $34 per share [1] - Picpay (PICS) raised $434 million by issuing 22.86 million shares at $19 per share [1] - Ethos Technologies (LIFE) raised $200 million by issuing 10.53 million shares at $19 per share [1] Group 2: Upcoming IPOs - Jaguar Uranium Corp. plans to list on NYSE MKT with the ticker JAGU on February 3, 2026, aiming to raise up to $30 million by issuing 6 million shares at $4 to $6 per share [3][5] - VeraDermics, Inc. plans to list on NYSE with the ticker MANE on February 4, 2026, aiming to raise up to $214 million by issuing 13.35 million shares at $14 to $16 per share [8] - Eikon Therapeutics, Inc. plans to list on NASDAQ with the ticker EIKN on February 5, 2026, aiming to raise up to $318 million by issuing 17.65 million shares at $16 to $18 per share [10] - Bob's Discount Furniture, Inc. plans to list on February 5, 2026, aiming to raise up to $370 million by issuing 19.45 million shares at $17 to $19 per share, with projected revenue of $1.719 billion and a net profit of $80.7 million for the first nine months of 2025 [14] - Forgent Power Solutions, Inc. plans to list on NYSE with the ticker FPS on February 5, 2026, aiming to raise up to $1.624 billion by issuing 56 million shares at $25 to $29 per share, with revenue of $283 million and a net profit of $15.56 million for the last three months ending September 30, 2025 [18] - Once Upon a Farm, PBC plans to list on February 6, 2026, aiming to raise up to $209 million by issuing 11 million shares at $17 to $19 per share, with revenue of $177 million and a net loss of $39.76 million for the first nine months of 2025 [22] - Liftoff Mobile, Inc. plans to list on NASDAQ with the ticker LFTO on February 6, 2026, aiming to raise up to $762 million by issuing 25.4 million shares at $26 to $30 per share, with revenue of $492 million and a net loss of $25.65 million for the first nine months of 2025 [25] - Agomab Therapeutics NV plans to raise up to $213 million by issuing 12.5 million shares at $15 to $17 per share, with no revenue and a loss of $45.15 million for the first nine months of 2025 [28]

Group 1 - Four IPOs and ten SPACs were priced this week, indicating a robust activity in the capital markets [2] - York Space Systems (YSS), a satellite manufacturer, priced its upsized IPO at the top of the range, successfully raising $629 million [2] - Additionally, three IPOs and five SPACs submitted filings, suggesting a continued interest in public offerings [2]

Group 1 - AgomAb Therapeutics, a Belgian biotech company, announced its IPO terms, planning to issue 12.5 million shares at a price range of $15 to $17 per share, aiming to raise $200 million [1][2] - The company focuses on developing TGFβ inhibitors for Crohn's disease and other fibrotic diseases, with a fully diluted market capitalization projected to reach $875 million based on the midpoint of the proposed price range [1] - The lead candidate drug, ontunisertib (AGMB-129), is a selective and potent oral small molecule inhibitor targeting ALK5 (TGFβR1), primarily aimed at treating fibrotic stricturing Crohn's disease (FSCD) [1] Group 2 - Another clinical-stage candidate, AGMB-447, is an inhaled ALK5 small molecule inhibitor for treating idiopathic pulmonary fibrosis (IPF) [2] - The company also has a preclinical candidate, a monoclonal antibody targeting liver cirrhosis, and has completed the necessary studies for new drug clinical trial applications [2] - AgomAb Therapeutics was founded in 2017 and plans to list on NASDAQ under the ticker "AGMB," with the IPO expected to be priced in February of this year [2]

Core Insights - Donovan Jones is an IPO research specialist with 15 years of experience analyzing investment opportunities for U.S. IPOs [1] - He leads the investing group IPO Edge, which provides actionable information on growth stocks through various resources [1] Group 1 - IPO Edge offers first-look IPO filings, previews on upcoming IPOs, an IPO calendar, a database of U.S. IPOs, and a guide to IPO investing [1] - The guide walks investors through the entire IPO lifecycle, including filing, listing, quiet period, and lockup expiration dates [1]

TABLE OF CONTENTS As filed with the United States Securities and Exchange Commission on January 29, 2026. Registration Statement No. 333-292790 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AgomAb Therapeutics NV (Exact name of registrant as specified in its charter) 2836 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Employer Identification Number) (State or Other Jurisdiction ...

TABLE OF CONTENTS As filed with the United States Securities and Exchange Commission on January 16, 2026. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AgomAb Therapeutics NV (Exact name of registrant as specified in its charter) 2836 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Employer Identification Number) Posthoflei 1/6 2600 Antwerpen, Belgium Tel: +32 3 318 ...